Suchergebnisse - "Mahon, Ronan"

PubPharm (21)

1

Comparative effectiveness of erenumab versus rimegepant for migraine prevention using matching-adjusted indirect comparison

enthalten in: Journal of comparative effectiveness research | 2024

von Mahon, R. | Tiwari, S. | Koch, M. | +5

2

Assessment of the relative effectiveness of erenumab compared with onabotulinumtoxinA for the prevention of chronic migraine

enthalten in: Current medical research and opinion | 2023

von Mahon, R. | Vo, P. | Pannagl, K. | +6

3

Cost-Effectiveness of Erenumab for the Preventive Treatment of Migraine in Patients with Prior Treatment Failures in Sweden

enthalten in: PharmacoEconomics | 2021

von Mahon, R. | Lang, A. | Vo, P. | +7

4

Cost-Effectiveness of Erenumab for the Preventive Treatment of Migraine in Patients with Prior Treatment Failures in Sweden

enthalten in: PharmacoEconomics | 2021

von Mahon, R. | Lang, A. | Vo, P. | +7

5

Cost-Effectiveness of Erenumab for the Preventive Treatment of Migraine in Patients with Prior Treatment Failures in Sweden

enthalten in: PharmacoEconomics | 2021

von Mahon, R. | Lang, A. | Vo, P. | +7

6

Cost-Effectiveness of Erenumab for the Preventive Treatment of Migraine in Patients with Prior Treatment Failures in Sweden

enthalten in: PharmacoEconomics | 2021

von Mahon, R. | Lang, A. | Vo, P. | +7

7

Economic evaluations in migraine : systematic literature review and a novel approach

enthalten in: Journal of medical economics | 2020

von Mahon, R. | Huels, J. | Hacking, V. | +8

8

Modelling the Cost-Effectiveness of Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone Using a Novel Markov Exacerbation-Based Approach

enthalten in: International journal of chronic obstructive pulmonary disease | 2020

von Lakhotia, B. | Mahon, R. | Gutzwiller, F. | +3

9

Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD : FLAME-based modelling in a Swedish population

enthalten in: Respiratory research | 2017

von Bjermer, L. | van Boven, J. | Costa-Scharplatz, M. | +6

10

Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population

enthalten in: Respiratory research | 2017

von Bjermer, L. | van Boven, J. | Costa-Scharplatz, M. | +6